Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Status: Recruiting
Location: See all (51) locations...
Study Type: Observational
SUMMARY
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Participants who, according to the treating physician's decision and in line with the local package label, are newly initiated on nemolizumab (Nemluvio®) for the treatment of PN.
• Participants greater than or equal to (\>=) 18 years of age.
• Participants who signed the written informed consent form (ICF).
Locations
United States
Alabama
Galderma Investigational Site # 8893
RECRUITING
Birmingham
Arizona
Galderma Investigational Site # 7060
RECRUITING
Phoenix
Galderma Investigational Site # 7077
RECRUITING
Phoenix
Galderma Investigational Site # 7067
RECRUITING
Tucson
California
Galderma Investigational Site # 7074
RECRUITING
Corona
Galderma Investigational Site # 6836
RECRUITING
Fountain Valley
Galderma Investigational Site # 8224
RECRUITING
Fremont
Galderma Investigational Site # 7064
RECRUITING
Santa Monica
Colorado
Galderma Investigational Site # 7061
RECRUITING
Castle Rock
Connecticut
Galderma Investigational Site # 7059
RECRUITING
Fairfield
Florida
Galderma Investigational Site # 7087
RECRUITING
Coral Gables
Galderma Investigational Site # 7063
RECRUITING
Cutler Bay
Galderma Investigational Site # 7078
RECRUITING
Miami
Galderma Investigational Site # 7070
RECRUITING
North Miami Beach
Galderma Investigational Site # 7091
RECRUITING
Tampa
Illinois
Galderma Investigational Site # 7058
NOT_YET_RECRUITING
Chicago
Indiana
Galderma Investigational Site # 8142
RECRUITING
Indianapolis
Massachusetts
Galderma Investigational Site # 7065
RECRUITING
Brighton
Maryland
Galderma Investigational Site # 8012
RECRUITING
Glendale
Galderma Investigational Site # 7068
RECRUITING
Rockville
Michigan
Galderma Investigational Site # 7066
RECRUITING
Auburn Hills
Galderma Investigational Site # 7071
RECRUITING
Caledonia
Galderma Investigational Site # 7072
RECRUITING
Troy
Galderma Investigational Site # 7053
RECRUITING
Waterford
Missouri
Galderma Investigational Site # 7057
RECRUITING
Lee's Summit
Galderma Investigational Site # 7076
RECRUITING
St Louis
New Hampshire
Galderma Investigational Site # 7055
RECRUITING
Portsmouth
New York
Galderma Investigational Site # 7080
RECRUITING
Auburn
Galderma Investigational Site # 7052
RECRUITING
East Syracuse
Galderma Investigational Site # 8282
RECRUITING
Mount Kisco
Galderma Investigational Site # 7051
RECRUITING
New York
Galderma Investigational Site # 7056
RECRUITING
New York
Ohio
Galderma Investigational Site # 7081
RECRUITING
Dayton
Pennsylvania
Galderma Investigational Site # 8559
RECRUITING
Philadelphia
Texas
Galderma Investigational Site # 8238
RECRUITING
Dallas
Galderma Investigational Site # 7062
RECRUITING
Edinburg
Galderma Investigational Site # 7088
RECRUITING
Grapevine
Galderma Investigational Site # 7069
RECRUITING
Sugar Land
Virginia
Galderma Investigational Site # 7079
RECRUITING
Vienna
Other Locations
Germany
Galderma Investigational Site # 6387
RECRUITING
Ahaus
Galderma Investigational Site # 6385
RECRUITING
Berlin
Galderma Investigational Tracker Site # 6172
RECRUITING
Berlin
Galderma Investigational Site # 6386
RECRUITING
Bielefeld
Galderma Investigational Site # 6369
RECRUITING
Erlangen
Galderma Investigational Site # 6370
NOT_YET_RECRUITING
Haslach
Galderma Investigational Site # 6374
RECRUITING
Karlsruhe
Galderma Investigational Site # 5437
RECRUITING
Kiel
Galderma Investigational Site # 6384
RECRUITING
Koblenz
Galderma Investigational Site # 6373
RECRUITING
Mainz
Galderma Investigational Site # 6371
RECRUITING
Oberursel
Galderma Investigation Site # 6367
RECRUITING
Rostock
Contact Information
Primary
Galderma Research and Development
clinical.studies@galderma.com
817-961-5000
Time Frame
Start Date: 2025-08-11
Estimated Completion Date: 2027-11-30
Participants
Target number of participants: 600
Treatments
Nemolizumab
Participants with moderate-to-severe PN who are receiving nemolizumab (Nemluvio®) in routine clinical practice will be observed for approximately 12 months.
Related Therapeutic Areas
Sponsors
Leads: Galderma R&D